These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26143184)

  • 1. Impact of insufficient drug efficacy of antiparkinson agents on patient's quality of life: a cross-sectional study.
    Tsugawa J; Onozawa R; Fukae J; Mishima T; Fujioka S; Tsuboi Y
    BMC Neurol; 2015 Jul; 15():105. PubMed ID: 26143184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of early morning off in Parkinson's disease on patient quality of life and caregiver burden.
    Onozawa R; Tsugawa J; Tsuboi Y; Fukae J; Mishima T; Fujioka S
    J Neurol Sci; 2016 May; 364():1-5. PubMed ID: 27084204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
    Santos-García D; de la Fuente-Fernández R
    J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease: a survey of patients and neurologists.
    Fargel M; Grobe B; Oesterle E; Hastedt C; Rupp M
    Clin Drug Investig; 2007; 27(3):207-18. PubMed ID: 17305415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
    Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
    Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early DEtection of wEaring off in Parkinson disease: the DEEP study.
    Stocchi F; Antonini A; Barone P; Tinazzi M; Zappia M; Onofrj M; Ruggieri S; Morgante L; Bonuccelli U; Lopiano L; Pramstaller P; Albanese A; Attar M; Posocco V; Colombo D; Abbruzzese G;
    Parkinsonism Relat Disord; 2014 Feb; 20(2):204-11. PubMed ID: 24275586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors impacting on quality of life in Parkinson's disease: results from an international survey.
    Global Parkinson's Disease Survey (GPDS) Steering Committee.
    Mov Disord; 2002 Jan; 17(1):60-7. PubMed ID: 11835440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between Quality of Life and severity of Parkinson's Disease by assessing an optimal cut-off point on the Parkinson's Disease questionnaire (PDQ-39) as related to the Hoehn & Yahr (H&Y) scale.
    Galeoto G; Berardi A; Colalelli F; Pelosin E; Mezzarobba S; Avanzino L; Valente D; Tofani M; Fabbrini G
    Clin Ter; 2022 May; 173(3):243-248. PubMed ID: 35612339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pain in Parkinson's Disease: A Cross-Sectional Study of Its Prevalence, Types, and Relationship to Depression and Quality of Life.
    Valkovic P; Minar M; Singliarova H; Harsany J; Hanakova M; Martinkova J; Benetin J
    PLoS One; 2015; 10(8):e0136541. PubMed ID: 26309254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study.
    Amboni M; Stocchi F; Abbruzzese G; Morgante L; Onofrj M; Ruggieri S; Tinazzi M; Zappia M; Attar M; Colombo D; Simoni L; Ori A; Barone P; Antonini A;
    Parkinsonism Relat Disord; 2015 Jun; 21(6):644-9. PubMed ID: 25899545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voiding dysfunction in patients with Parkinson's disease: impact of neurological impairment and clinical parameters.
    Sammour ZM; Gomes CM; Barbosa ER; Lopes RI; Sallem FS; Trigo-Rocha FE; Bruschini H; Srougi M
    Neurourol Urodyn; 2009; 28(6):510-5. PubMed ID: 19191278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease.
    Bianchi MLE; Riboldazzi G; Mauri M; Versino M
    Neurol Sci; 2019 Feb; 40(2):275-279. PubMed ID: 30382437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
    Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Tison F; Rascol O;
    Eur J Neurol; 2017 Dec; 24(12):1532-1538. PubMed ID: 28940893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of sleep quality on caregiver burden in Parkinson's disease.
    Bartolomei L; Pastore A; Meligrana L; Sanson E; Bonetto N; Minicuci GM; Marsala SZ; Mesiano T; Bragagnolo L; Antonini A
    Neurol Sci; 2018 May; 39(5):835-839. PubMed ID: 29445989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Underactive and overactive bladders are related to motor function and quality of life in Parkinson's disease.
    Liu Z; Uchiyama T; Sakakibara R; Yamamoto T
    Int Urol Nephrol; 2015 May; 47(5):751-7. PubMed ID: 25792006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries.
    Hechtner MC; Vogt T; Zöllner Y; Schröder S; Sauer JB; Binder H; Singer S; Mikolajczyk R
    Parkinsonism Relat Disord; 2014 Sep; 20(9):969-74. PubMed ID: 24953743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rest energy expenditure in Parkinson's disease: role of disease progression and dopaminergic therapy.
    Capecci M; Petrelli M; Emanuelli B; Millevolte M; Nicolai A; Provinciali L; Ceravolo MG
    Parkinsonism Relat Disord; 2013 Feb; 19(2):238-41. PubMed ID: 23182312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.